Prevalence of LLDAS
| Placebo (n=102) | Anifrolumab 300 mg (n=99) | Anifrolumab 1,000 mg (n=104) | |
| Duration of observed study time per patient (years), mean (SD) | 0.84 (0.29) | 0.95 (0.20) | 0.89 (0.25) |
| Patients with at least one episode of LLDAS, n (%) | 36 (35.3) | 51 (51.5) | 48 (46.2) |
| Cumulative LLDAS duration per patient (years), mean (SD) | 0.12 (0.22) | 0.24 (0.29) | 0.19 (0.27) |
| Percentage of observed study time in LLDAS per patient (years), mean (SD) | 12.4 (22.0) | 24.0 (28.7) | 19.4 (27.1) |
LLDAS, Lupus Low Disease Activity State.